CMEA Capital portfolio company Arcadia Biosciences, Inc. announces closing of $33 million round of series D preferred share equity financing. Arcadia Biosciences, Inc. is an agricultural biotechnology company that concentrates only on developing technologies and products, which in coming times will benefit the environment and human health.
San Francisco, CA -- (SBWIRE) -- 06/25/2014 -- CMEA Capital portfolio company Arcadia Biosciences, Inc. announces closing of $33 million round of series D preferred share equity financing. Arcadia Biosciences, Inc. is an agricultural biotechnology company that concentrates only on developing technologies and products, which in coming times will benefit the environment and human health. With an aim to speed up the development and commercial launch of products primarily based on the company’s agronomic performance and product quality, they planned to utilize profits from the financing.
CMEA Capital along with the other investors participated in the round that headed with an investment of $30 million from Mandala Capital Limited. In addition, the Series D round completed with a total equity capital raised by Arcadia amounts to $101 million.
Besides, Eric Rey, President and CEO of Arcadia mentions for CMEA Capital, “Multiple products based on Arcadia’s agronomic performance and product quality traits are currently in late-stage commercial development, and our SONOVA® 400 GLA Safflower Oil is already on market. The Series D funding enables us to continue working closely with our licensees and partners to accelerate progress, provide key data for commercial regulatory approvals, and pursue opportunities with new partners.”
The company has a strong network of corporate, investment, and entrepreneurial relationships, thus, invests in both early and late stage ventures. From the inception, they have successfully managed seven venture capital funds representing investments in excess of $1.2 billion.
About CMEA Capital
CMEA Capital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.
For more information, please visit- http://www.cmea.com/about-us/
Contact Details
1 Letterman Drive
Building C, Suite CM500
San Francisco, CA 94129
Phone: (415) 352-1520
Fax: (415) 352-1524
Press Relations Contact
For press inquiries only, please contact:
Contact: Victoria Jenks
Email: victoria@cmea.com
Phone: (415) 352-1520